Immunoglobulin Levels After Switching From Ocrelizumab to Ofatumumab in Multiple Sclerosis
Studies immunoglobulin levels in adults with multiple sclerosis who switch to ofatumumab.
Plain-language title generated from the registry record
Registry title: Switch to Ofatumumab and Level of Immunoglobulins
Key facts
- Where
- Lille, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07625800, who can take part
Where in France
- CHU de LilleLille, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Lille
- Trial code
- NCT07625800
- Record updated
- 30 October 2026
- Original description
This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up.Read full original descriptionShow less
Switch to Ofatumumab and Level of Immunoglobulins
This real-life study aims to describe IgG levels after switching from ocrelizumab 600 mg IV every 6 to 8 months in Patients with Multiple Sclerosis (PwMS) to ofatumumab 20 mg SC every month and showing a decreasing level of IgG during treatment by ocrelizumab in real life practice in France over 24 months of follow-up.
The primary objective is therefore to determine if the downward trend of IgG observed during ocrelizumab treatment is modified after a switch to ofatumumab, in PwMS treated during at least 18 months of ocrelizumab in real life practice, over 24 months of follow-up.
Inclusion: Adult patients (≥ 18 years old) who had been treated with ocrelizumab for a relapsing form of Multiple Sclerosis according to the ocrelizumab marketing authorization (MA) treatment regimen for at least 18 months; Patients with a decrease of IgG at a minimum of two consecutive dosages (around six months apart) during ocrelizumab treatment*; Patients already switched or switching from ocrelizumab to ofatumumab treatment (decision independent from the study*); Patients agreeing to participate to the study; Able to provide their non-opposition; At the discretion of the investigator, if a benefit for patients is expected based on their experience and depending on patient's characteristics.
Exclusion: Patients with ocrelizumab dose spacing > 8 months in the last 18 months before switch; Patient who underwent an immunoglobulin supplementation therapy within 18 months before the switch; Ongoing or planned pregnancy.